Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190(BCR-ABL)-positive acute lymphoblastic leukemia

Leukemia. 2002 Oct;16(10):2159-60. doi: 10.1038/sj.leu.2402729.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzamides
  • Fusion Proteins, bcr-abl / metabolism*
  • Humans
  • Imatinib Mesylate
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / therapeutic use*
  • Male
  • Middle Aged
  • Piperazines
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • Pyrimidines / administration & dosage
  • Pyrimidines / therapeutic use*
  • Recombinant Proteins
  • Recurrence
  • Remission Induction*

Substances

  • Benzamides
  • Interferon alpha-2
  • Interferon-alpha
  • Piperazines
  • Pyrimidines
  • Recombinant Proteins
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl